Early test of potential new weight loss combo shows promise
NCT ID NCT06916065
Summary
This early-stage study tested the safety and how the body processes two experimental drugs, eloralintide alone and combined with tirzepatide, for weight management. It involved 188 adults who were overweight or obese, giving weekly injections under the skin for up to 26 weeks. Researchers primarily tracked side effects and measured how much drug entered the bloodstream and how long it stayed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anaheim Clinical Trials, LLC
Anaheim, California, 92801, United States
-
Fortrea Clinical Research Unit
Daytona Beach, Florida, 32117, United States
-
Fortrea Clinical Research Unit
Dallas, Texas, 75247, United States
Conditions
Explore the condition pages connected to this study.